Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

Completed · Phase 2 · Has a placebo group

Conditions studied: Myocardial Infarction

In brief

The purpose of this study is to see if a naturally-occurring hormone called erythropoietin changes the action of platelets in the blood. Patients with heart attacks are treated with medicines to reduce the clotting action of platelets. This study is trying to determine whether erythropoietin alters the clotting action of platelets in patients receiving anti-platelet medicines. It is important to understand the effects of erythropoietin on platelets since preliminary studies in animals suggest that erythropoietin may protect the heart from damage during a heart attack.

Key facts

Study ID

NCT00367991

Run by

Yale University

People needed

44

Starts

2006-11-01

Expected to finish

2008-03-01

Last updated by the study team

2018-01-12

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 21-75 years
• Clinical evidence of acute myocardial infarction (MI) with total or sub-total occlusion on angiogram
• Status post percutaneous revascularization procedure for acute MI with TIMI 3 flow
• Ongoing clinically-indicated treatment with aspirin, thienopyridines

You may not qualify if…

• Hemodynamic instability/shock or severe congestive heart failure
• Time from onset of chest pain to revascularization procedure > 16 hours
• Use of intravenous thrombolytic agents for treatment of MI
• Known need for additional revascularization procedures

Where it is running

• Yale University — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.